Teva's antitrust decision over 'disparagement' of MS drug published by EU
MLex Summary: The European Commission has revealed the full details of its 462.6 million-euro fine against Teva Pharmaceuticals for distorting the market for a multiple-sclerosis treatment. The regulator found that Teva artificially...To view the full article, register now.
Already a subscriber? Click here to view full article